News Astellas builds in protein degraders with PeptiDream deal Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.
Partner Content Partner Content Ipsen presents on oral peptides innovations, advances and de... Ipsen presents on oral peptides innovations & delivery
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face